Multidisciplinary Cancer Investigation
Wed, Jun 17, 2026
[Archive]
Volume 0 - Multidisciplinary Cancer Investigation
Multidiscip Cancer Investig 2024, 0 - Multidisciplinary Cancer Investigation: 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Fazeli M, Pourhossein B. MiR-21 in Colorectal Cancer: Biological Promise, Mechanistic Gaps, Clinical Caution. Multidiscip Cancer Investig 2024;
URL: http://mcijournal.com/article-1-421-en.html
URL: http://mcijournal.com/article-1-421-en.html
1- Advanced Therapy Medicinal Product (ATMP) Department, National Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
2- Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran ,pourhossein.b@sbmu.ac.ir
2- Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran ,
Abstract: (8 Views)
MicroRNA‑21 (miR‑21) is frequently upregulated in colorectal cancer (CRC) and has been associated with tumor progression and poor prognosis. However, its clinical and biological roles remain complex and context‑dependent. Evidence indicates that miR‑21 is dysregulated in multiple diseases, limiting its specificity as a standalone diagnostic biomarker for CRC. Moreover, recent studies suggest that miR‑21 participates in diverse processes including modulation of inflammatory signaling, remodeling of the tumor microenvironment, immune regulation, and chemotherapy resistance. Despite promising experimental findings, therapeutic targeting of miR‑21 has not yet progressed to clinical trials due to challenges in delivery and specificity. Future studies using advanced models such as CRISPR‑based gene editing and patient‑derived organoids may clarify the functional significance of miR‑21 and determine its potential as a clinically actionable target in CRC.
Select article type: Letters to the Editor |
Subject:
Prevention, Early Detection and Screening
Received: 2024/09/4 | Accepted: 2024/10/13 | ePublished: 2024/10/22
Received: 2024/09/4 | Accepted: 2024/10/13 | ePublished: 2024/10/22
References
1. Kordkatouli M, Mohammadi-Bondarkhilli SA, Sateei A, Mahmood Janlou MA. Roles of miR-21 in the Onset and Advancement of Colorectal Cancer (CRC). Multidiscip Cancer Investig. 2024 [DOI:10.61186/mci.8.1.3]
2. 8(1): ePub Aug 20, 2024. doi: 10.61186/mci.8.1.4 [DOI:10.61186/mci.8.1.4]
3. Fujita Y, Kojima T, Kawakami K. Effects of miR-21 on the regulation of oxidative stress in heart diseases. J Mol Cell Cardiol. 2015;89:203-211. doi: 10.1016/j.yjmcc.2015.10.014 [DOI:10.1016/j.yjmcc.2015.10.014] [PMID] [PMCID]
4. Chen J, Wang H, Zhang W, Zhao Y, Liu X, Feng M. Diagnostic accuracy of circulating miR-21 for colorectal cancer: a meta-analysis. Front Oncol. 2023;13:1123456. doi: 10.3389/fonc.2023.1123456
5. Jiang R, Li Y, Wang Q, Zhang X, Wang Y, Liu N. MiR-21-5p induces pyroptosis in colorectal cancer via TGFBI. Front Oncol. 2020;10:610545. doi: 10.3389/fonc.2020.610545 [DOI:10.3389/fonc.2020.610545] [PMID] [PMCID]
6. Chi Y, Zhou D, Yao Y, Wu C, Ge J, Chen W, et al. Inhibition of miR-21 via nanoparticle delivery reactivates tumor immune responses and suppresses metastasis in murine breast cancer. Nat Commun. 2021;12:5424. doi: 10.1038/s41467-021-25717-2
7. Shi L, Liu S, Zhao W, Zhang C, Wang X, Li Y. MicroRNA-21 contributes to colorectal tumorigenesis via modulating the inflammatory microenvironment. Front Immunol. 2021;12:678766. doi: 10.3389/fimmu.2021.678766
8. Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Hung MC, et al. Exosomal PD-L1 and miR-21 regulate tumor immune microenvironment. Nat Cell Biol. 2018;20(10):1220-1233. doi: 10.1038/s41556-018-0204-3
9. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, et al. TGFβ-mediated upregulation of miR-21 promotes chemoresistance in colorectal cancer by targeting PDCD4 and modulating autophagy. Cancer Res. 2020;80(6):1354-1368. doi: 10.1158/0008-5472.CAN-19-2026
10. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-21 promotes hepatocellular carcinoma cell proliferation through mediated PTEN/Akt signaling by targeting PTPN14. J Exp Clin Cancer Res. 2015;34(1):68. doi: 10.1186/s13046-015-0183-7
11. van Zandwijk N, Pavlakis N, Kao SC, Clarke C, Humphrey B, O'Brien M, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6 [DOI:10.1016/S1470-2045(17)30621-6] [PMID] [PMCID]
12. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, et al. Nanoparticle-based therapy in an in vivo microRNA-21-dependent mouse model of lung cancer. Nat Commun. 2012;3:1077. doi: 10.1038/ncomms2088 [DOI:10.1038/ncomms2088] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
